An investigation into the Effects of Intravenous Vitamin C on Pulmonary CT Findings and Clinical Outcomes of Patients with COVID 19 Pneumonia A Randomized Clinical Trial
Tehrani et al.
, An investigation into the Effects of Intravenous Vitamin C on Pulmonary CT Findings and Clinical Outcomes of..
, Urology Journal, doi:10.22037/uj.v18i.6863
RCT 54 late stage patients, 18 treated with IV vitamin C (2g every 6h for 5 days), showing significant relative improvements in oxygen saturation and respiratory rate.
risk of death, 87.1% lower, RR 0.13, p = 0.13, treatment 0 of 18 (0.0%), control 4 of 26 (15.4%), NNT 6.5, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
hospitalization time, 17.6% lower, relative time 0.82, p = 0.23, treatment 18, control 26.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Tehrani et al., 8 Nov 2021, Randomized Controlled Trial, Iran, peer-reviewed, 10 authors, average treatment delay 9.0 days.
Abstract: An investigation into the effects of intravenous vitamin C on pulmonary CT
findings and clinical outcomes of patients with COVID 19 pneumonia A
Randomized Clinical Trial
Shabnam Tehrani 1 ,Davood Yadegarynia 2, Alireza Abrishami 3 , Hamideh Moradi 1, Babak
Gharaei 4, Masoomeh Raoufi 5, Fatemeh Maghsudi nejad 6, Shahnaz Sali 2, Neda Khabiri 1,
Sara Abolghasemi 2*
1. Labbafinejad Clinical Research Center, Shahid Beheshti University of Medical Sciences,
2. Infectious Diseases and Tropical Medicine Research Center, Shahid Beheshti University
of Medical Sciences, Tehran, Iran
3. Assistant Professor of Radiology, Department of Radiology, Shahid Labbafinejad
hospital,Shahid Beheshti University of Medical Sciences,Tehran,Iran
4. Anesthesiology department, school of medicine, Shahid Beheshti University of Medical
Sciences, Tehran, Iran
5. Department of radiology, school of medicine, Imam Hossein hospital, Shahid Beheshti
University of Medical Sciences, Tehran, Iran;
6. School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
*Corresponding author: Sara Abolghasemi, . Infectious Diseases and Tropical Medicine
Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Purpose:In late December 2019, a series of unexplained cases of pneumonia were reported in
Wuhan, China. On January 12, 2020, the World Health Organization temporarily named the virus
responsible for the emerging cases of pneumonia as the 2019 coronavirus. Acute respiratory
distress syndrome (ARDS) due to Covid-19 has rapidly spread around the world, and while no
specific treatment or vaccine has been reported, mortality rates remain high. One of the suggested
treatments for cellular damage in the pathogenesis of ARDS caused by the coronavirus is the
administration of high doses of intravenous vitamin C. Considering the paucity of literature on the
therapeutic effects of high doses of intravenous vitamin C in patients with ARDS resulting from
the coronavirus, this study was conducted to assess this therapeutic supplement in these patients.
Materials and Methods: This study was performed as a single-center clinical trial in patients with
a documented diagnosis of COVID-19 pneumonia. 54 eligible patients with moderate to severe
COVID-19 symptoms, based on specific inclusion and exclusion criteria, were included in the
investigation and randomly divided into two groups. The control group consisted of 26 patients
who received standard treatment, whereas the treatment group was comprised of 18 patients
administered intravenous vitamin C at a dose of 2 g every 6 hours for 5 days in addition to
standard treatment. Demographic characteristics, underlying diseases, length of hospital stay, and
mortality rates were reviewed and collected. Oxygen saturation, respiratory rates, serum C
Reactive Protein (CRP) levels, lymphopenia and lung parenchymal involvement on CT were
investigated at the time of admission and on the sixth day after hospitalization. Finally, all
variables were analyzed with IBM SPSS Statistics 23 software and a significant statistical
difference was defined for all variables, P <0.05.
Results: Of these variables, the amount of oxygen saturation in the vitamin C group increased
significantly from 86±5% on the first day of hospitalization to 90±3% on the sixth day of
hospitalization (P value=0.02). Also, the respiratory rate in the vitamin C group decreased
significantly from 27±3..
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC
provide treatment protocols.